Large Renewal Order Moves to Third Quarter, Still Posts Third Highest Quarterly Revenue
Simulations Plus Signs Research Collaboration Agreement with FDA
Company to Work with FDA on Mechanistic IVIVC Modeling
Simulations Plus Announces Quarterly Cash Dividend
Cash dividend declared of $0.05 per share
Simulations Plus Sets Date for 1st Quarter 2014 Earnings Release and Conference Call
Conference Call to be on Thursday, January 9, at 4:15 PM ET
Simulations Plus Reports First-Quarter FY2014 Financial Results
Net sales increase 15.3% to first quarter record $2.641 million; Earnings up 16.7%
Faruqi & Faruqi, LLP Launches An Investigation Against Simulations Plus, Inc. (SLP) For Potential Breaches Of Fiduciary Duties By Its Board Of Directors
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Simulations Plus, Inc.
Simulations Plus Reports Preliminary Revenues for First Fiscal Quarter FY2014
Revenues Increase 14.9% for New Record 1st Quarter
Simulations Plus Announces Change in Chief Financial Officer
John R. Kneisel, CPA, to Replace Momoko Beran, Retiring after More Than 20 Years of Service
Simulations Plus to Present at the LD MICRO Sixth Annual Conference
Leading Provider of Simulation and Modeling Software for Pharmaceutical Discovery and Development to Present on December 3, 2013
Simulations Plus Reports FY2013 and Fourth Quarter FY2013 Financial Results
Fiscal Year Pharmaceutical Software and Services Up 6.6%
Largest Chinese CRO, WuXi PharmaTech, Purchases Multiyear ADMET Predictor License
Toxicity predictions to be used to supplement in vitro data as a service
Simulations Plus Announces Another Quarterly Cash Dividend Increase
Cash dividend increased to $0.04 per share
U.S. FDA Adds Licenses of GastroPlus™ Software
Office of Clinical Pharmacology Interested in Program’s Drug-Drug Interaction Capabilities
Simulations Plus Reports Preliminary Revenues for Fourth Fiscal Quarter and Fiscal Year 2013
Full-Year Revenue Up 6.6%; 6th Consecutive Profitable Year
Simulations Plus Releases GastroPlus™ 8.5
Software Upgrade Adds Numerous Capabilities and User Convenience Features
Simulations Plus Completes Molecule Design Phase of Second NCE Project, Issues RFQs for Molecule Synthesis
Company Uses Proprietary Software Tools to Design New Molecules for COX-2 Inhibitors
Simulations Plus Completes Collaboration with Bayer HealthCare to Enhance Important Property Prediction in ADMET Predictor™
Prediction of Ionization Constants Key to Many Other Property Predictions
Simulations Plus Announces Quarterly Cash Dividend Increase
Board increases cash dividend again to $0.03 per share
Simulations Plus Releases MedChem Studio™ 3.5 and MedChem Designer™ 2.5
Software Upgrades Further Expand Powerful Data Mining and Molecule Design Programs, Extend Technological Lead of Simulations Plus